Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7883156 | 0.70 | PDE9A (0.49) | SMN1; SMN2HTTL3MBTL1ALDH1A1RECQL | |
| SCHEMBL7876154 | 0.68 | PDE9A (0.56) | SMN1; SMN2HTTL3MBTL1ALDH1A1RECQL | |
| Oxypurinol SCHEMBL8256863 | 0.66 | ALDH1A1 (0.53) | SMN1; SMN2HTTL3MBTL1ALDH1A1RECQL | |
| SCHEMBL16712554 | 0.66 | ALDH1A1 (0.59) | SMN1; SMN2HTTALDH1A1RECQLNPC1 | |
| SCHEMBL17869808 | 0.66 | USP7 (0.38) | — | |
| SCHEMBL20214280 | 0.64 | ALDH1A1 (0.50) | SMN1; SMN2HTTALDH1A1RECQLNPC1 | |
| SCHEMBL481407 | 0.63 | DYRK1A (0.53) | SMN1; SMN2HTTALDH1A1RECQLNPC1 | |
| SCHEMBL6642975 | 0.63 | ALDH1A1 (0.53) | SMN1; SMN2HTTALDH1A1RECQLNPC1 | |
| SCHEMBL4497867 | 0.63 | ALDH1A1 (0.57) | SMN1; SMN2HTTALDH1A1RECQLNPC1 | |
| SCHEMBL20213747 | 0.62 | GAA (0.49) | SMN1; SMN2HTTALDH1A1RECQLNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018030-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | VALO HEALTH, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20210332052-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2021-10-28 | — | — | US | disclosed |
| US-10934299-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10377760-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20180339988-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2018-11-29 | — | — | US | disclosed |
| US-9902728-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-20160185785-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH, INC. | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377760-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | USP7, UBA7, UBXN1 | SMN1; SMN2 1753/4885HTT 1292/4885L3MBTL1 1264/4885 |
| US-12018030-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | USP7, UBA7, UBXN1 | SMN1; SMN2 1782/4885HTT 1255/4885L3MBTL1 1217/4885 |
| US-20210332052-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBA7, UBXN1 | SMN1; SMN2 1782/4885HTT 1255/4885L3MBTL1 1217/4885 |
| US-20160185785-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBA7, UBXN1 | SMN1; SMN2 1782/4885HTT 1255/4885L3MBTL1 1217/4885 |
| US-10934299-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | USP7, UBA7, UBXN1 | SMN1; SMN2 1782/4885HTT 1255/4885L3MBTL1 1217/4885 |
| US-20180339988-A1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBA7, UBXN1 | SMN1; SMN2 1753/4885HTT 1292/4885L3MBTL1 1264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.